Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 9/20 | 0.77 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.58 |
| ▸ | PIM1 | P11309 | 1/20 | 0.58 |
| ▸ | AKT1 | P31749 | 1/20 | 0.58 |
| ▸ | FLT3 | P36888 | 1/20 | 0.58 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.58 |
| ▸ | IP6K1 | Q92551 | 8/20 | 0.54 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.53 |
| ▸ | IP6K3 | Q96PC2 | 5/20 | 0.52 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.51 |
| ▸ | IP6K2 | Q9UHH9 | 3/20 | 0.50 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4619270 | 0.87 | PARP1 (1.00) | PARP1CHEK1PIM1AKT1FLT3 | |
| SCHEMBL29966835 | 0.87 | PARP1 (1.00) | PARP1CHEK1PIM1AKT1FLT3 | |
| SCHEMBL10280684 | 0.83 | PARP1 (0.63) | PARP1CHEK1PIM1AKT1FLT3 | |
| SCHEMBL19251312 | 0.78 | PARP1 (0.56) | PARP1CHEK1PIM1AKT1FLT3 | |
| SCHEMBL30101979 | 0.78 | PARP1 (0.59) | PARP1CHEK1PIM1AKT1FLT3 | |
| SCHEMBL18642669 | 0.78 | PARP1 (0.51) | PARP1CHEK1PIM1PIM3 | |
| SCHEMBL29709603 | 0.77 | PARP1 (1.00) | PARP1CHEK1PIM1AKT1FLT3 | |
| SCHEMBL2191067 | 0.77 | PARP1 (1.00) | PARP1CHEK1PIM1AKT1FLT3 | |
| SCHEMBL8622180 | 0.77 | ACVR1 (0.73) | PARP1CHEK1PIM1AKT1FLT3 | |
| SCHEMBL22042406 | 0.76 | IP6K1 (0.61) | PARP1CHEK1PIM1AKT1FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115260164-B | Preparation method, structural composition and application of novel 4 (3H) -quinazolinone analogue in antitumor drugs | 杭州星鳌生物科技有限公司 | 2024-03-26 | — | — | CN | disclosed |
| CN-115260164-A | Preparation method and structural composition of novel 4 (3H) -quinazolinone analogue and application of analogue in antitumor drugs | 杭州星鳌生物科技有限公司 | 2022-11-01 | — | — | CN | disclosed |
| US-10005739-B2 | Quinazolinone and isoquinolinone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2018-06-26 | — | — | US | disclosed |
| US-10005739-B2 | Quinazolinone and isoquinolinone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2018-06-26 | — | — | US | disclosed |
| US-10005739-B2 | Quinazolinone and isoquinolinone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2018-06-26 | — | — | US | disclosed |
| US-20160272595-A1 | QUINAZOLINONE AND ISOQUINOLINONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-09-22 | — | — | US | disclosed |
| US-20160272595-A1 | QUINAZOLINONE AND ISOQUINOLINONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-09-22 | — | — | US | disclosed |
| US-20160272595-A1 | QUINAZOLINONE AND ISOQUINOLINONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-09-22 | — | — | US | disclosed |
| EP-3061749-A1 | QUINAZOLINONE AND ISOQUINOLINONE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2016-08-31 | — | — | EP | disclosed |
| EP-3061749-A1 | QUINAZOLINONE AND ISOQUINOLINONE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2016-08-31 | — | — | EP | disclosed |
| WO-2015164374-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. (US) | 2015-10-29 | — | — | WO | disclosed |
| WO-2015060373-A1 | QUINAZOLINONE AND ISOQUINOLINONE DERIVATIVE | 中外製薬株式会社 | 2015-04-30 | — | — | WO | disclosed |
| US-20120214807-A1 | COMPOUNDS USEFUL AS ANTAGONISTS OF CCR2 | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-8067457-B2 | Compounds useful as antagonists of CCR2 | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20090197884-A1 | Compounds Useful as Antagonists of CCR2 | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-08-06 | — | — | US | disclosed |
| WO-2007053498-A1 | COMPOUNDS USEFUL AS ANTAGONISTS OF CCR2 | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
| WO-1993012795-A1 | QUINAZOLIN-4(3H)-ONE DERIVATIVES AS ANTICOCCIDIAL AGENTS | GLAZER EDWARD A (US) | 1993-07-08 | — | — | WO | disclosed |
| US-4920224-A | CHEMICAL INTERMEDIATES | PFIZER INC. (US) | 1990-04-24 | — | — | US | disclosed |
| US-4849518-A | ANTIPROTOZOA IN POULTRY | PFIZER INC. (US) | 1989-07-18 | — | — | US | disclosed |
| US-4762838-A | Quinazolin-4(3H)-one derivatives as anticoccidial agents | PFIZER INC. (US) | 1988-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272595-A1 | QUINAZOLINONE AND ISOQUINOLINONE DERIVATIVE | NQO2, SDHA, CYP3A5 | PARP1 870/4885CHEK1 1511/4885PIM1 1289/4885 |
| US-20120214807-A1 | COMPOUNDS USEFUL AS ANTAGONISTS OF CCR2 | CCR2, CCR1, CXCR3 | PARP1 2282/4885CHEK1 4034/4885PIM1 3341/4885 |
| US-20090197884-A1 | Compounds Useful as Antagonists of CCR2 | CCR2, CCR1, CXCR3 | PARP1 2282/4885CHEK1 4034/4885PIM1 3341/4885 |
| US-10005739-B2 | Quinazolinone and isoquinolinone derivative | NQO2, SDHA, CYP3A5 | PARP1 870/4885CHEK1 1511/4885PIM1 1289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.